Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Rhea-AI Summary
Clene (Nasdaq: CLNN) said management will participate in a panel discussion at the Maxim Growth Summit and will host 1x1 investor meetings on October 22, 2025 in New York City. The panel is titled Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Meeting requests for 1x1 sessions are available through a Maxim representative.
The company and its subsidiary Clene Nanomedicine focus on mitochondrial health and neuronal protection for diseases including ALS and MS.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CLNN gained 3.49%, reflecting a moderate positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $95M at that time.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor meetings.
Date: October 22, 2025
Location: New York City, NY
Panel Discussion: Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories
1x1 Meetings: Please contact your Maxim representative
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Clene (CLNN) participate in the Maxim Growth Summit?
What panel will Clene (CLNN) join at the Maxim Growth Summit?
How can investors request 1x1 meetings with Clene (CLNN) at the Maxim Growth Summit?
Which Clene subsidiaries are referenced for the Maxim Growth Summit appearance?
What therapeutic areas will Clene (CLNN) highlight at the panel on October 22, 2025?
Where is the Maxim Growth Summit session featuring Clene (CLNN) located?
